StockData
AC Immune SA logo

AC Immune SA (ACIU) stock

ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 13, 2026Score 3/30
$2.10−0.01 (-0.47%)

Close on Nov 18, 2026Market cap $213.66MP/E –Yield –

AC Immune revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

AC Immune's revenue for the twelve months ending Dec 31, 2022 was CHF 3.94M. For fiscal 2025 it was CHF 3.57M, down 86.9% from the year before. Over ten years it grew -21.3% a year on average. The highest annual figure on record is CHF 110.46M in fiscal 2019.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 3.57M-86.9%
FY2024Dec 31, 2024CHF 27.31M+84.5%
FY2023Dec 31, 2023CHF 14.80M+276.1%
FY2022Dec 31, 2022CHF 3.94M–
FY2021Dec 31, 2021CHF 0-100.0%
FY2020Dec 31, 2020CHF 15.43M-86.0%
FY2019Dec 31, 2019CHF 110.46M+1498.0%
FY2018Dec 31, 2018CHF 6.91M-65.9%
FY2017Dec 31, 2017CHF 20.26M-12.7%
FY2016Dec 31, 2016CHF 23.21M-40.6%
FY2015Dec 31, 2015CHF 39.09M–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2025Jun 30, 2025CHF 1.31M-66.8%
Q2 FY2024Jun 30, 2024CHF 687.00K–
Q2 FY2023Jun 30, 2023CHF 0–
Q4 FY2022Dec 31, 2022CHF 1.00K–
Q3 FY2022Sep 30, 2022CHF 3.93M+180.4%
Q2 FY2022Jun 30, 2022CHF 0-100.0%
Q4 FY2021Dec 31, 2021CHF 0-100.0%
Q3 FY2021Sep 30, 2021CHF 0-100.0%
Q4 FY2018Dec 31, 2018CHF 1.40M-91.5%
Q3 FY2018Sep 30, 2018CHF 2.31M+114.6%
Q2 FY2018Jun 30, 2018CHF 2.03M+169.3%
Q1 FY2018Mar 31, 2018CHF 1.46M-27.3%
Q4 FY2017Dec 31, 2017CHF 16.42M–
Q3 FY2017Sep 30, 2017CHF 1.07M–
Q2 FY2017Jun 30, 2017CHF 753.00K–
Q1 FY2017Mar 31, 2017CHF 2.01M–

More AC Immune figures

See a number that looks wrong?